Get the Stockscreener App
145.26
6.43%
8.9575
Revolution Medicines Inc stock is traded at $145.26, with a volume of 5.63M.
It is up +6.43% in the last 24 hours and up +52.92% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
See More
Previous Close:
$136.30
Open:
$136.5
24h Volume:
5.63M
Relative Volume:
1.78
Market Cap:
$28.75B
Revenue:
$742.00K
Net Income/Loss:
$-1.13B
P/E Ratio:
-24.55
EPS:
-5.9165
Net Cash Flow:
$-913.73M
1W Performance:
+50.65%
1M Performance:
+52.92%
6M Performance:
+205.39%
1Y Performance:
+297.75%
1-Day Range:
$134.66
$145.16
1-Week Range:
$94.63
$145.15
52-Week Range:
$34.00
$145.15
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
650-481-6801
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
145.05 | 19.11B | 742.00K | -1.13B | -913.73M | -5.9165 |
VRTX
Vertex Pharmaceuticals Inc
|
442.39 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.85 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
827.24 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
337.76 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.20 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Feb-27-26 | Resumed | UBS | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Investors Purchase High Volume of Revolution Medicines Call Options (NASDAQ:RVMD) - MarketBeat
RVMD Maintains by RBC Capital -- Price Target Raised to $162 - GuruFocus
RVMD Maintained by Wells Fargo -- Price Target Raised to $167 - GuruFocus
Revolution Medicines (NASDAQ:RVMD) Given New $167.00 Price Target at Wells Fargo & Company - MarketBeat
Revolution Medicines Stock Soars on Breakthrough Cancer Data - TipRanks
RVMD Maintained by Evercore ISI Group -- Price Target Raised to $200 - GuruFocus
RVMD Reiterated by Wedbush -- Price Target Maintained at $147.00 - GuruFocus
RVMD Maintained by Guggenheim -- Price Target Raised to $175 - GuruFocus
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report) - FinancialContent
Why Did Oncology Stock Revolution Medicines (RVMD) Gain 41% Monday? - Investorideas.com
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
RVMD Maintained by HC Wainwright & Co. -- Price Target Raised to $169 - GuruFocus
RBC Raises Price Target on Revolution Medicines to $162 From $140, Keeps Outperform, Speculative Risk - marketscreener.com
H.C. Wainwright raises Revolution Medicines price target to $169 - Investing.com
Pancreatic cancer pill shown to nearly double overall survival time, drug company says - The Hill
H.C. Wainwright raises Revolution Medicines price target to $169 By Investing.com - Investing.com Canada
Revolution Medicines (RVMD) Is Up 42.9% After Phase 3 Daraxonrasib Survival Data And $750M Equity Raise – Has The Bull Case Changed? - Yahoo Finance
Revolution Medicines Doubles Pancreatic Cancer Survival in Phase 3 Trial — Is RVMD Stock a Buy at $136? - TradingKey
Baillie Gifford & Co. Invests $15.53 Million in Revolution Medicines, Inc. $RVMD - MarketBeat
US biotech seeks quick FDA approval after improved survivability with cancer candidate - medwatch.com
Revolution Medicines Stock Surges After Trial Data: Is Biotech Back? - EBC Financial Group
Revolution Medicines (RVMD) Sees Potential Surge Following Phase III Trial Success - GuruFocus
Revolution Medicines (RVMD) Soars to All-Time High on Stellar Cancer Treatment Trial - Insider Monkey
Revolution Medicines (RVMD) Plans $1 Billion in Offerings to Bol - GuruFocus
Revolution’s daraxonrasib nails endpoints in pancreatic cancer trial - BioWorld News
Revolution Medicines plans $1 billion dual offering By Investing.com - Investing.com India
RVMD Stock Jumps As Analysts Hike Price Targets On Pancreatic Cancer Bets - timothysykes.com
Revolution Medicines shares pop after pancreatic cancer drug trial win - CNBC
Revolution Medicines shares jump on breakthrough pancreatic cancer trial results - MSN
Revolution Medicines, Inc. Announces Proposed Offerings Of Common Stock And Convertible Senior Notes - TradingView — Track All Markets
Revolution Medicines plans $1B combined equity and convertible note offerings - MSN
Revolution Medicines (RVMD) files $750M share sale; $250M convertible notes planned - Stock Titan
Revolution Medicines (NASDAQ: RVMD) seeks $250M via convertible notes, concurrent $750M stock sale - Stock Titan
Revolution Medicines plans $1 billion dual offering - Investing.com
Top Biotech Catapults On 'Unprecedented' Results In Cancer - Investor's Business Daily
Revolution Medicines Announces Unprecedented Survival Gains with Daraxonrasib in Late-Stage Pancreatic Cancer Study - BBN Times
U.S. Markets Rose Monday; Revolution Medicines Topped Leaders - Barron's
Leerink Partners Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $147.00 - MarketBeat
Revolution Medicines seeks $1B to fund cancer-drug R&D, launch prep - Stock Titan
Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial - MedCity News
Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy? - Barchart.com
Revolution Medicines stock hits all-time high at 132.41 USD By Investing.com - Investing.com Australia
RVMD Stock Rallies As Analysts Hike Price Targets On Trial Momentum - timothysykes.com
RVMD Maintained by Oppenheimer -- Price Target Raised to $165 - GuruFocus
Revolution Medicines (RVMD) Stock Surges 38.7% - GuruFocus
Revolution Medicines surges 38% on pancreatic cancer breakthrough - CryptoRank
Revolution Medicines Announces Breakthrough in Pancreatic Cancer Treatment with daraxonrasib - GuruFocus
Revolution Medicines (RVMD) Sees Remarkable 37.9% Surge - GuruFocus
Revolution Medicines: PDAC Data Wows Wall StreetJury's Out On Further Upside (RVMD) - Seeking Alpha
RVMD Stock Jumps As Analysts Hike Targets On Trial Hopes - StocksToTrade
Revolution Medicines reports positive Phase 3 results for daraxonrasib in pancreatic cancer By Investing.com - Investing.com India
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):